Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
macular degeneration
Pharma
Regeneron sees more regulatory issues, sales declines for Eylea
As regulatory delays continue to plague Regeneron's Eylea, quarterly sales for the treatment have dropped below $1B for the first time since 2018.
Kevin Dunleavy
Apr 29, 2026 12:05pm
Regeneron faces category headwinds for eye disease drug Eylea
Jan 30, 2026 11:41am
Regeneron wins 2 Eylea nods, ramping up competition with Roche
Nov 20, 2025 11:53am
Manufacturing issues cause FDA to delay decisions on Eylea HD
Aug 20, 2025 2:32pm
Apellis expects sales of Syfovre to decline in Q1
Feb 28, 2025 3:05pm
FDA gives thumbs-up to Roche's Susvimo as treatment for DME
Feb 4, 2025 3:15pm
